Sonoma Pharmaceuticals (SNOA) Stock Analysis & AI Equity Report
Sonoma Pharmaceuticals (SNOA) overview
Sonoma Pharmaceuticals (SNOA) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 19.5m and operating profit of USD -2.5m; the year-end share price was 2.13 USD and market capitalisation was USD 3.8m. Sonoma Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Sonoma Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals develops and produces stabilized hypochlorous acid products for wound care, eye care, dermatological conditions, podiatry, animal health, and disinfection. Its offerings include wound cleansers, skin sprays, gels, and products for conditions such as irritation, scars, acne, and eczema. The company sells directly and through distribution partners in the United States and international markets.
Generate the Sonoma Pharmaceuticals report
Sonoma Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Sonoma Pharmaceuticals and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Sonoma Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.